| A U.S. district court ruled against the validity of Bayer Schering Pharma's patent for its contraceptive drug Yasmin, the German drug company said late on Monday.span id=midArticle_byline/spanspan id=midArticle_0/spanpThis was the result of a patent challenge by generic manufacturer Barr Laboratories, Bayer said in a statement./pspan id=midArticle_1/spanpBayer disagrees with the court's decision and will consider its legal options in this regard, the company added./pspan id=midArticle_2/spanpBayer Schering's contraceptive drug Yasmin has annual sales of more than one billion euros. Sales of Yasmin in the United States came in at 321 million euros ($486.9 million) last year, it said./p |
|
Law Firm News RSS Feed
